Ralfinamide (INN; development codes NW-1029, FCE-26742A, and PNU-0154339E) is a multimodal drug which is under investigation by Newron Pharmaceuticals for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain. It has a relatively complex pharmacology, acting as a mixed voltage-gated sodium channel blocker (including Nav1.7), N-type calcium channel blocker, noncompetitive NMDA receptor antagonist, and monoamine oxidase B inhibitor. As of 2020, it was in phase III clinical trials. In 2010 it failed a phase II trial for lower back pain. Encouraging Phase II results have been announced for neuropathic pain.
See also List of investigational analgesics Safinamide, different fluorine position Evenamide, structurally-related antipsychotic in development Lacosamide, used for partial-onset seizures and diabetic neuropathic pain Ziconotide, FDA approved peptide for chronic neuropathic pain
References
External links Ralfinamide - Newron Pharmaceuticals Archived 2015-01-03 at the Wayback Machine